BAM
CRBP icon

Belpointe Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Belpointe Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22
Closed -$160 – 1133
2023
Q1 		$160 Buy
+22
New +$96 ﹤0.01% 3692

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Belpointe Asset Management's CRBP Position: Q2 2023 in Review

Belpointe Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2023, closing a stake of 22 shares — an estimated $160 sold.

Belpointe Asset Management first reported a position in CRBP in Q1 2023 and held it in 1 quarter. The position peaked at $160 in Q1 2023. 28 funds tracked by Wall St. Rank hold CRBP as of Q2 2023.

  • Belpointe Asset Management reported no remaining Corbus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 22 Corbus Pharmaceuticals shares in Q2 2023, an estimated $160.
  • Belpointe Asset Management first reported a position in Corbus Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Corbus Pharmaceuticals position peaked at $160 in Q1 2023.
  • 28 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.